Mouse Anti-human CD55-PE/FITC Conjugated antibody

Home > Product > Antibody > Mouse Anti-human CD55-PE/FITC Conjugated antibody

CD 55; CD55; CD55 antigen; CD55 Cromer blood group system; CD55 molecule; CD55 molecule, decay accelerating factor for complement (Cromer blood group); Cd55a; Complement decay accelerating factor; Complement decay-accelerating factor; Complement

Cat:

SLM30084M-PE-FITC

Species Reactivity：

Human,

Format：

Liquid

Storage instructions：

Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of ant

Buffer：

0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Concentration：

1mg/ml

Clonality：

Monoclonal

Isotype：

IgG

Applications：

Flow-Cyt=1:50-200not yet tested in other applications.optimal dilutions/concentrations should be determined by the end user.

Host：

Mouse

Calculated MW：

35kDa

prev next

Unit:

Price: $596.00

Product PDFs

Datasheet: Down Datasheet

Other Information
Citations
Protein Attributes
Feedback Wall

background:
This gene encodes a protein involved in the regulation of the complement cascade. The encoded glycoprotein is also known as the decay-accelerating factor (DAF); binding of DAF to complement proteins accelerates their decay, disrupting the cascade and preventing damage to host cells. Antigens present on the DAF glycoprotein constitute the Cromer blood group system (CROM). Two alternatively spliced transcripts encoding different proteins have been identified. The predominant transcript encodes a membrane-bound protein expressed on cells exposed to plasma component proteins but an alternatively spliced transcript produces a soluble protein present at much lower levels. Additional, alternatively spliced transcript variants have been described, but their biological validity has not been determined.

Function:
This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade.

Subunit:
Monomer (major form) and non-disulfide-linked, covalent homodimer (minor form). Binds to coxsackievirus A21, coxsackieviruses B1, B3 and B5, human enterovirus 70, human echoviruses 6, 7, 11, 12, 20 and 21 capsid proteins and acts as a receptor for these viruses.

Subcellular Location:
Isoform 1: Cell membrane; Single-pass type I membrane protein.
Isoform 2: Cell membrane; Lipid-anchor, GPI-anchor.

Tissue Specificity:
Expressed on the plasma membranes of all cell types that are in intimate contact with plasma complement proteins. It is also found on the surfaces of epithelial cells lining extracellular compartments, and variants of the molecule are present in body fluids and in extracellular matrix.

Post-translational modifications:
The Ser/Thr-rich domain is heavily O-glycosylated.

Similarity:
Belongs to the receptors of complement activation (RCA) family.
Contains 4 Sushi (CCP/SCR) domains.

Database links:

Entrez Gene: 1604 Human

Omim: 12548 Human

SwissProt: P08174 Human

Unigene: 126517 Human

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Product Feedback Wall